Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now ...
LONDON: Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health.
Closed Loop Medicine holds over 65 filings across 16 patent families, marking a significant milestone in its mission to deliver precision medicine at scale. The Company continues to expand its strong intellectual property foundation to safeguard the scalability of its innovations in personalized dosing, novel drug forms and drug-digital combination therapies.
In the rapidly-established GLP-1 market, Closed Loop Medicine has recognized the potential in delivering personalized solutions that address both the unpredictability of weight loss and the adverse effects that may otherwise limit patient adherence to weight management programs. The Company’s IP covers dose optimization according to patient-specific factors such as degree of calorie restriction or exercise, providing an opportunity for the development of personalized co-therapies enhancing existing GLP-1 medicines.
The latest patent granted by the US Patent Office extends Closed Loop Medicine’s cardiometabolic capabilities into DOAC therapy, enabling more personalized and effective anticoagulation treatment. This patent supports AI-powered precision dosing for patients requiring DOACs, improving safety and efficacy in stroke prevention and other cardiovascular conditions.
Dr Hakim Yadi, CEO and co-Founder of Closed Loop Medicine, says: “Establishing a strong and differentiated patent portfolio is central to our leadership in AI-enabled personalized medicine. These patents reinforce our ability to deliver smarter, AI-enabled pharmacometric dosing solutions. Not only to improve clinical outcomes and optimize treatment for cardiometabolic diseases with novel drug forms, but also software enhancements of existing drugs, the latter receiving timely support with the FDA’s recent Prescription Drug Use-Related Software PDURS guidance”
To learn more about Closed Loop Medicine and its mission to deliver precision care for all, please visit: www.closedloopmedicine.com
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that six abstracts have been accepted at the 2025 ASCO…
Udemy (Nasdaq: UDMY), a leading AI-powered reskilling platform, today announced the launch of Role Play, a new AI-powered offering that helps learners…
#AI--LambdaTest, a unified agentic AI and cloud engineering platform, has announced the launch of its Automation MCP Server, a breakthrough solution designed…
Dubai Electricity and Water Authority (DEWA) has started to receive applications for participation in the 27th edition of the Water, Energy, Technology,…